-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Axsome Therapeutics, Lowers Price Target to $250

Benzinga·11/03/2026 14:37:54
Listen to the news
Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $275 to $250.